The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The intestinal barrier: a pivotal role in health, inflammation, and cancer [0.03%]
肠道屏障：在健康、炎症和癌症中起到关键作用
Markus F Neurath,David Artis,Christoph Becker
Markus F Neurath
The intestinal barrier serves as a boundary between the mucosal immune system in the lamina propria and the external environment of the intestinal lumen, which contains a diverse array of microorganisms and ingested environmental factors, i...
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study [0.03%]
住院失代偿性肝硬化患者的急性肾损伤的全球流行病学：国际腹水俱乐部的GLOBAL AKI前瞻性、多中心、队列研究
Kavish R Patidar,Ann T Ma,Adrià Juanola et al.
Kavish R Patidar et al.
Background: Acute kidney injury (AKI) is a serious complication of cirrhosis. A systematic, global characterisation of AKI occurring in patients with cirrhosis is lacking. We therefore aimed to assess global differences i...
Marlies Ostermann
Marlies Ostermann
The urgent need for implementation science to achieve hepatitis C elimination [0.03%]
实现丙型肝炎消除迫切需要实施科学
Guillaume Fontaine,Natalie Taylor,Julie Bruneau et al.
Guillaume Fontaine et al.
Combination locoregional and systemic therapies in hepatocellular carcinoma [0.03%]
肝细胞癌的局部区域和全身联合治疗
Bin-Yan Zhong,Wenzhe Fan,Justin J Guan et al.
Bin-Yan Zhong et al.
Locoregional therapies play a fundamental role in the treatment of patients with early and intermediate and locally advanced hepatocellular carcinomas. With encouraging recent advances in immunotherapy-based systemic therapies, locoregional...
Hepatitis C incidence targets among people who inject drugs: a long road ahead [0.03%]
注射毒品者的丙型肝炎发病率目标：路漫漫其修远兮
Ruth Zimmermann,Renke Lars Biallas
Ruth Zimmermann
Emerging evidence-based role for external-beam radiation therapy in hepatocellular carcinoma [0.03%]
外部束放射治疗在肝细胞癌中的新兴循证作用
Stephanie O Dudzinski,Neil B Newman,Jeff McIntyre et al.
Stephanie O Dudzinski et al.
The primary curative therapies for hepatocellular carcinoma are resection or liver transplantation. For patients requiring downstaging or who are unresectable at presentation, the landscape of local treatment options has vastly changed over...
Christian Tibor Josef Magyar,Luckshi Rajendran,Zhihao Li et al.
Christian Tibor Josef Magyar et al.
Hepatocellular carcinoma arises in the setting of cirrhosis in most cases, requiring multidisciplinary input to define resectability. In this regard, more precise surgical management considers patient factors and anatomical states, includin...
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis [0.03%]
全球、区域和国家层面的注射毒品人群中丙型肝炎病毒(HCV)感染发生率以及归因于注射毒品使用的新的年度HCV感染数量：多阶段分析
Adelina Artenie,Adam Trickey,Katharine J Looker et al.
Adelina Artenie et al.
Background: Measuring progress towards the WHO 2030 target for hepatitis C virus (HCV) elimination among people who inject drugs (PWID)-an incidence of two or fewer infections per 100 person-years-has been challenging due...